泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议

智通财经2025-12-31

智通财经APP讯，泽璟制药(688266.SH)发布公告，公司与艾伯维集团控股公司(注册地：百慕大)(以下简称“艾伯维”)就ZG006(Alveltamig)的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006(Alveltamig)在大中华区(为本协议之目的，包含中国大陆、香港特别行政区、澳门特别行政区)以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595724052?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-31 16:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595724052","market":"us","top_or_hot":-1,"title":"泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，泽璟制药(688266.SH)发布公告，公司与艾伯维集团控股公司(注册地：百慕大)(以下简称“艾伯维”)就ZG006(Alveltamig)的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006(Alveltamig)在大中华区(为本协议之目的，包含中国大陆、香港特别行政区、澳门特别行政区)以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1387689.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-31 16:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1387689.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，泽璟制药(688266.SH)发布公告，公司与艾伯维集团控股公司(注册地：百慕大)(以下简称“艾伯维”)就ZG006(Alveltamig)的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006(Alveltamig)在大中华区(为本协议之目的，包含中国大陆、香港特别行政区、澳门特别行政区)以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1387689.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688266","symbol_name":"泽璟制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1387689.html","article_id":"2595724052","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595724052","pubTimestamp":1767169654,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，泽璟制药 发布公告，公司与艾伯维集团控股公司就ZG006的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006在大中华区以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的开发与商业化权利。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688266":"泽璟制药","BK0239":"医药制造"},"translate_title":"Zejing Pharmaceuticals (688266. SH) and AbbVie reached a global strategic cooperation and licensing option agreement on the development and commercialization rights of ZG006","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1.5},"content_text":"智通财经APP讯，泽璟制药(688266.SH)发布公告，公司与艾伯维集团控股公司(注册地：百慕大)(以下简称“艾伯维”)就ZG006(Alveltamig)的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006(Alveltamig)在大中华区(为本协议之目的，包含中国大陆、香港特别行政区、澳门特别行政区)以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的开发与商业化权利。根据协议，泽璟将获得1亿美元的首付款，及基于临床进展的近期里程碑付款和与许可选择相关的付款最高6,000万美元;如艾伯维行使许可选择权，泽璟还有资格获得最高达10.75亿美元的里程碑付款，并就包含ZG006的产品在大中华区以外的净销售额收取从高个位数到中双位数的阶梯式特许权使用费。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595724052","isCrawlerRequest":true}